nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclopentolate—BCHE—kidney cancer	0.915	1	CbGaD
Cyclopentolate—CHRM3—ureter—kidney cancer	0.0194	0.778	CbGeAlD
Cyclopentolate—Punctate keratitis—Capecitabine—kidney cancer	0.00256	0.043	CcSEcCtD
Cyclopentolate—Hyperpyrexia—Paclitaxel—kidney cancer	0.00212	0.0356	CcSEcCtD
Cyclopentolate—CHRM3—renal system—kidney cancer	0.00154	0.0618	CbGeAlD
Cyclopentolate—CHRM3—kidney—kidney cancer	0.00149	0.0598	CbGeAlD
Cyclopentolate—Paralysis—Vincristine—kidney cancer	0.00143	0.024	CcSEcCtD
Cyclopentolate—BCHE—nephron tubule—kidney cancer	0.00138	0.0555	CbGeAlD
Cyclopentolate—Photophobia—Vinblastine—kidney cancer	0.00133	0.0222	CcSEcCtD
Cyclopentolate—Lacrimation increased—Sunitinib—kidney cancer	0.00127	0.0214	CcSEcCtD
Cyclopentolate—Abdominal distension—Temsirolimus—kidney cancer	0.00119	0.02	CcSEcCtD
Cyclopentolate—Gastroenteritis—Everolimus—kidney cancer	0.00115	0.0193	CcSEcCtD
Cyclopentolate—BCHE—cardiac atrium—kidney cancer	0.00113	0.0452	CbGeAlD
Cyclopentolate—Abdominal distension—Pazopanib—kidney cancer	0.00112	0.0189	CcSEcCtD
Cyclopentolate—Conjunctivitis—Temsirolimus—kidney cancer	0.00103	0.0173	CcSEcCtD
Cyclopentolate—Urinary retention—Everolimus—kidney cancer	0.00097	0.0163	CcSEcCtD
Cyclopentolate—Coma—Vincristine—kidney cancer	0.000908	0.0152	CcSEcCtD
Cyclopentolate—Abdominal distension—Everolimus—kidney cancer	0.000888	0.0149	CcSEcCtD
Cyclopentolate—Lacrimation increased—Paclitaxel—kidney cancer	0.000856	0.0144	CcSEcCtD
Cyclopentolate—Flushing—Pazopanib—kidney cancer	0.00083	0.0139	CcSEcCtD
Cyclopentolate—Conjunctivitis—Everolimus—kidney cancer	0.000765	0.0128	CcSEcCtD
Cyclopentolate—Abdominal distension—Sunitinib—kidney cancer	0.000742	0.0125	CcSEcCtD
Cyclopentolate—Conjunctivitis—Erlotinib—kidney cancer	0.000738	0.0124	CcSEcCtD
Cyclopentolate—Vision blurred—Pazopanib—kidney cancer	0.000734	0.0123	CcSEcCtD
Cyclopentolate—Convulsion—Temsirolimus—kidney cancer	0.000716	0.012	CcSEcCtD
Cyclopentolate—Lacrimation—Doxorubicin—kidney cancer	0.00071	0.0119	CcSEcCtD
Cyclopentolate—Lacrimation increased—Capecitabine—kidney cancer	0.000703	0.0118	CcSEcCtD
Cyclopentolate—Hallucination—Everolimus—kidney cancer	0.000703	0.0118	CcSEcCtD
Cyclopentolate—Urinary retention—Vincristine—kidney cancer	0.000686	0.0115	CcSEcCtD
Cyclopentolate—Ataxia—Vincristine—kidney cancer	0.000678	0.0114	CcSEcCtD
Cyclopentolate—Coordination abnormal—Capecitabine—kidney cancer	0.000659	0.0111	CcSEcCtD
Cyclopentolate—Flushing—Everolimus—kidney cancer	0.000655	0.011	CcSEcCtD
Cyclopentolate—Dry mouth—Pazopanib—kidney cancer	0.000648	0.0109	CcSEcCtD
Cyclopentolate—Paralysis—Doxorubicin—kidney cancer	0.000601	0.0101	CcSEcCtD
Cyclopentolate—Somnolence—Temsirolimus—kidney cancer	0.0006	0.0101	CcSEcCtD
Cyclopentolate—Vision blurred—Everolimus—kidney cancer	0.000579	0.00972	CcSEcCtD
Cyclopentolate—Tremor—Everolimus—kidney cancer	0.000576	0.00967	CcSEcCtD
Cyclopentolate—Flushing—Sorafenib—kidney cancer	0.000569	0.00955	CcSEcCtD
Cyclopentolate—Agitation—Everolimus—kidney cancer	0.000565	0.00948	CcSEcCtD
Cyclopentolate—Somnolence—Pazopanib—kidney cancer	0.000565	0.00948	CcSEcCtD
Cyclopentolate—Vertigo—Vinblastine—kidney cancer	0.000554	0.00931	CcSEcCtD
Cyclopentolate—Flushing—Sunitinib—kidney cancer	0.000547	0.00919	CcSEcCtD
Cyclopentolate—Ataxia—Paclitaxel—kidney cancer	0.000539	0.00904	CcSEcCtD
Cyclopentolate—Convulsion—Vinblastine—kidney cancer	0.000535	0.00897	CcSEcCtD
Cyclopentolate—Convulsion—Everolimus—kidney cancer	0.000533	0.00894	CcSEcCtD
Cyclopentolate—Gastroenteritis—Capecitabine—kidney cancer	0.00053	0.0089	CcSEcCtD
Cyclopentolate—Flushing—Dactinomycin—kidney cancer	0.000518	0.0087	CcSEcCtD
Cyclopentolate—Dry mouth—Everolimus—kidney cancer	0.000512	0.00859	CcSEcCtD
Cyclopentolate—Abdominal distension—Paclitaxel—kidney cancer	0.000498	0.00837	CcSEcCtD
Cyclopentolate—Hallucination—Vincristine—kidney cancer	0.000496	0.00833	CcSEcCtD
Cyclopentolate—Tachycardia—Everolimus—kidney cancer	0.00049	0.00822	CcSEcCtD
Cyclopentolate—Pruritus—Temsirolimus—kidney cancer	0.000477	0.00801	CcSEcCtD
Cyclopentolate—Vasodilation procedure—Doxorubicin—kidney cancer	0.000475	0.00797	CcSEcCtD
Cyclopentolate—Vasodilation—Doxorubicin—kidney cancer	0.000475	0.00797	CcSEcCtD
Cyclopentolate—Lacrimation increased—Doxorubicin—kidney cancer	0.000453	0.0076	CcSEcCtD
Cyclopentolate—Pruritus—Pazopanib—kidney cancer	0.000449	0.00755	CcSEcCtD
Cyclopentolate—Urinary retention—Capecitabine—kidney cancer	0.000447	0.0075	CcSEcCtD
Cyclopentolate—Somnolence—Everolimus—kidney cancer	0.000446	0.00749	CcSEcCtD
Cyclopentolate—Convulsion—Sunitinib—kidney cancer	0.000445	0.00747	CcSEcCtD
Cyclopentolate—Dry mouth—Sorafenib—kidney cancer	0.000444	0.00746	CcSEcCtD
Cyclopentolate—Ataxia—Capecitabine—kidney cancer	0.000442	0.00742	CcSEcCtD
Cyclopentolate—Conjunctivitis—Paclitaxel—kidney cancer	0.000429	0.0072	CcSEcCtD
Cyclopentolate—Dry mouth—Sunitinib—kidney cancer	0.000427	0.00718	CcSEcCtD
Cyclopentolate—Rash—Temsirolimus—kidney cancer	0.000425	0.00714	CcSEcCtD
Cyclopentolate—Coordination abnormal—Doxorubicin—kidney cancer	0.000425	0.00713	CcSEcCtD
Cyclopentolate—Dermatitis—Temsirolimus—kidney cancer	0.000425	0.00713	CcSEcCtD
Cyclopentolate—Abdominal distension—Capecitabine—kidney cancer	0.000409	0.00686	CcSEcCtD
Cyclopentolate—Rash—Pazopanib—kidney cancer	0.000401	0.00672	CcSEcCtD
Cyclopentolate—Dermatitis—Pazopanib—kidney cancer	0.0004	0.00672	CcSEcCtD
Cyclopentolate—Agitation—Vincristine—kidney cancer	0.000399	0.0067	CcSEcCtD
Cyclopentolate—Vertigo—Vincristine—kidney cancer	0.00039	0.00655	CcSEcCtD
Cyclopentolate—Coma—Doxorubicin—kidney cancer	0.000381	0.0064	CcSEcCtD
Cyclopentolate—Convulsion—Vincristine—kidney cancer	0.000376	0.00632	CcSEcCtD
Cyclopentolate—Flushing—Paclitaxel—kidney cancer	0.000368	0.00617	CcSEcCtD
Cyclopentolate—Pruritus—Everolimus—kidney cancer	0.000355	0.00596	CcSEcCtD
Cyclopentolate—Conjunctivitis—Capecitabine—kidney cancer	0.000352	0.00591	CcSEcCtD
Cyclopentolate—Pruritus—Erlotinib—kidney cancer	0.000342	0.00575	CcSEcCtD
Cyclopentolate—Vision blurred—Paclitaxel—kidney cancer	0.000325	0.00546	CcSEcCtD
Cyclopentolate—Tremor—Paclitaxel—kidney cancer	0.000323	0.00542	CcSEcCtD
Cyclopentolate—Agitation—Paclitaxel—kidney cancer	0.000317	0.00532	CcSEcCtD
Cyclopentolate—Rash—Everolimus—kidney cancer	0.000316	0.00531	CcSEcCtD
Cyclopentolate—Dermatitis—Everolimus—kidney cancer	0.000316	0.0053	CcSEcCtD
Cyclopentolate—Vertigo—Paclitaxel—kidney cancer	0.00031	0.0052	CcSEcCtD
Cyclopentolate—Pruritus—Sorafenib—kidney cancer	0.000308	0.00517	CcSEcCtD
Cyclopentolate—Rash—Erlotinib—kidney cancer	0.000305	0.00512	CcSEcCtD
Cyclopentolate—Dermatitis—Erlotinib—kidney cancer	0.000305	0.00512	CcSEcCtD
Cyclopentolate—Flushing—Capecitabine—kidney cancer	0.000302	0.00507	CcSEcCtD
Cyclopentolate—Somnolence—Gemcitabine—kidney cancer	0.000299	0.00502	CcSEcCtD
Cyclopentolate—Convulsion—Paclitaxel—kidney cancer	0.000299	0.00502	CcSEcCtD
Cyclopentolate—Pruritus—Sunitinib—kidney cancer	0.000296	0.00498	CcSEcCtD
Cyclopentolate—Dry mouth—Paclitaxel—kidney cancer	0.000287	0.00482	CcSEcCtD
Cyclopentolate—Ataxia—Doxorubicin—kidney cancer	0.000285	0.00478	CcSEcCtD
Cyclopentolate—Tachycardia—Paclitaxel—kidney cancer	0.000275	0.00461	CcSEcCtD
Cyclopentolate—Rash—Sorafenib—kidney cancer	0.000275	0.00461	CcSEcCtD
Cyclopentolate—Dermatitis—Sorafenib—kidney cancer	0.000274	0.0046	CcSEcCtD
Cyclopentolate—Vision blurred—Capecitabine—kidney cancer	0.000267	0.00448	CcSEcCtD
Cyclopentolate—Tremor—Capecitabine—kidney cancer	0.000265	0.00445	CcSEcCtD
Cyclopentolate—Rash—Sunitinib—kidney cancer	0.000264	0.00443	CcSEcCtD
Cyclopentolate—Dermatitis—Sunitinib—kidney cancer	0.000264	0.00443	CcSEcCtD
Cyclopentolate—Abdominal distension—Doxorubicin—kidney cancer	0.000264	0.00443	CcSEcCtD
Cyclopentolate—Vertigo—Capecitabine—kidney cancer	0.000254	0.00427	CcSEcCtD
Cyclopentolate—Somnolence—Paclitaxel—kidney cancer	0.00025	0.0042	CcSEcCtD
Cyclopentolate—Rash—Dactinomycin—kidney cancer	0.00025	0.0042	CcSEcCtD
Cyclopentolate—Pruritus—Gemcitabine—kidney cancer	0.000238	0.00399	CcSEcCtD
Cyclopentolate—Dry mouth—Capecitabine—kidney cancer	0.000236	0.00396	CcSEcCtD
Cyclopentolate—Drowsiness—Doxorubicin—kidney cancer	0.000233	0.00392	CcSEcCtD
Cyclopentolate—Conjunctivitis—Doxorubicin—kidney cancer	0.000227	0.00381	CcSEcCtD
Cyclopentolate—Tachycardia—Capecitabine—kidney cancer	0.000225	0.00378	CcSEcCtD
Cyclopentolate—Rash—Vincristine—kidney cancer	0.000223	0.00375	CcSEcCtD
Cyclopentolate—Dermatitis—Vincristine—kidney cancer	0.000223	0.00375	CcSEcCtD
Cyclopentolate—Rash—Gemcitabine—kidney cancer	0.000212	0.00356	CcSEcCtD
Cyclopentolate—Dermatitis—Gemcitabine—kidney cancer	0.000212	0.00356	CcSEcCtD
Cyclopentolate—Pruritus—Paclitaxel—kidney cancer	0.000199	0.00334	CcSEcCtD
Cyclopentolate—Flushing—Doxorubicin—kidney cancer	0.000195	0.00327	CcSEcCtD
Cyclopentolate—Rash—Paclitaxel—kidney cancer	0.000177	0.00298	CcSEcCtD
Cyclopentolate—Dermatitis—Paclitaxel—kidney cancer	0.000177	0.00298	CcSEcCtD
Cyclopentolate—Vision blurred—Doxorubicin—kidney cancer	0.000172	0.00289	CcSEcCtD
Cyclopentolate—Agitation—Doxorubicin—kidney cancer	0.000168	0.00281	CcSEcCtD
Cyclopentolate—Vertigo—Doxorubicin—kidney cancer	0.000164	0.00275	CcSEcCtD
Cyclopentolate—Pruritus—Capecitabine—kidney cancer	0.000163	0.00274	CcSEcCtD
Cyclopentolate—Convulsion—Doxorubicin—kidney cancer	0.000158	0.00265	CcSEcCtD
Cyclopentolate—Dry mouth—Doxorubicin—kidney cancer	0.000152	0.00255	CcSEcCtD
Cyclopentolate—Rash—Capecitabine—kidney cancer	0.000146	0.00244	CcSEcCtD
Cyclopentolate—Dermatitis—Capecitabine—kidney cancer	0.000146	0.00244	CcSEcCtD
Cyclopentolate—Tachycardia—Doxorubicin—kidney cancer	0.000145	0.00244	CcSEcCtD
Cyclopentolate—Somnolence—Doxorubicin—kidney cancer	0.000132	0.00222	CcSEcCtD
Cyclopentolate—Pruritus—Doxorubicin—kidney cancer	0.000105	0.00177	CcSEcCtD
Cyclopentolate—Rash—Doxorubicin—kidney cancer	9.39e-05	0.00158	CcSEcCtD
Cyclopentolate—Dermatitis—Doxorubicin—kidney cancer	9.38e-05	0.00157	CcSEcCtD
